徳島大学 / 教育研究者総覧 --- 中山知彦

検索:

徳島大学 ⟩ 病院 ⟩ 先端医科医療開発研究プロジェクト ⟩
徳島大学 ⟩ 病院 ⟩ 診療科 ⟩ 脳·神経·精神科 ⟩ 精神科神経科 ⟩
徳島大学 ⟩ 病院 ⟩ 診療科 ⟩ 脳·神経·精神科 ⟩ 心身症科 ⟩
徳島大学 ⟩ 医学部 ⟩ 医学科 ⟩ 情報統合医学講座 ⟩ 精神医学分野 ⟩

(researchmapへのインポート用ファイル) [PDF解説] [researchmapへの自動反映について]

研究活動

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

1.	Tomohiko Nakayama, Hidehiro Umehara, Kazuaki Mawatari, Yukiko Tomioka, Tomohiro Yoshida, Hiroya Matsuda, Yui Matsumoto, Rumiko Masuda, Toshiharu Kamishikiryo, Manabu Fuchikami, Masahito Nakataki, Akira Takahashi, Atsushi Tajima, Go Okada and Shusuke Numata : Alterations of Blood Plasma Metabolites, Including Kynurenine and Tryptophan, in Bipolar Disorder, Neuropsychiatric Disease and Treatment, 21, 1067-1073, 2025. (キーワード) kynurenine / metabolome / メタボロミクス (metabolomics) / psychiatric disorder / tryptophan (出版サイトへのリンク) ● Publication site (DOI): 10.2147/NDT.S508021 (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-105006852907 (DOI: 10.2147/NDT.S508021, Elsevier: Scopus)
2.	Toshiyuki Shirai, Satoshi Okazaki, Takaki Tanifuji, Shusuke Numata, Tomohiko Nakayama, Tomohiro Yoshida, Kentaro Mouri, Ikuo Otsuka, Noboru Hiroi and Akitoyo Hishimoto : Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis., Schizophrenia, 10, 1, 108, 2024. (要約) Schizophrenia is a common chronic psychiatric disorder that causes age-related dysfunction. The life expectancy in patients with schizophrenia is 10 years shorter than that in the general population because of the higher risk of other diseases, such as cardiovascular diseases. Aging studies based on DNA methylation status have received considerable attention. Several epigenetic age accelerations and predicted values of aging-related proteins (GrimAge and GrimAge2 components) have been analyzed in multiple diseases. However, no studies have investigated up to GrimAge and GrimAge2 components between patients with schizophrenia and controls. Therefore, we aimed to conduct multiple regression analyses to investigate the association between schizophrenia and epigenetic age accelerations and GrimAge and GrimAge2 components in seven cohorts. Furthermore, we included patients with first-episode psychosis whose illness duration was often shorter than schizophrenia in our analysis. We integrated these results with meta-analyses, noting the acceleration of GrimAge, GrimAge2, and DunedinPACE, and increase in adrenomedullin, beta-2 microglobulin, cystatin C, and plasminogen activation inhibitor-1 levels, in patients with schizophrenia or first-episode psychosis. These results corroborated the finding that patients with schizophrenia had an increased risk of diabetes, cardiovascular disease, and cognitive dysfunction from a biological perspective. Patients with schizophrenia and first-episode psychosis showed differences in the results when compared with controls. Such analyses may lead to the development of novel therapeutic targets to patients with schizophrenia or relevant diseases from the perspective of aging in the future. (徳島大学機関リポジトリ) ● Metadata: 2013067 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41537-024-00531-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39548083 ● Search Scopus @ Elsevier (PMID): 39548083 ● Search Scopus @ Elsevier (DOI): 10.1038/s41537-024-00531-8 (徳島大学機関リポジトリ: 2013067, DOI: 10.1038/s41537-024-00531-8, PubMed: 39548083)
3.	中山知彦, 沼田周助 : 統合失調症の精神症状に関する評価尺度—PANSS，BPRS，SANS，SAPS., 精神医学, 66, 5, 520-525, 2024年.
4.	Tomoki Ozaki, Yuta Yoshino, Ayumi Tachibana, Hideaki Shimizu, Takaaki Mori, Tomohiko Nakayama, Kazuaki Mawatari, Shusuke Numata, Junichi Iga, Akira Takahashi, Tetsuro Ohmori and Shu-ichi Ueno : Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study)., Scientific Reports, 12, 1, 15205, 2022. (要約) Alzheimer's disease (AD) is a progressive disease, and the number of AD patients is increasing every year as the population ages. One of the pathophysiological mechanisms of AD is thought to be the effect of metabolomic abnormalities. There have been several studies of metabolomic abnormalities of AD, and new biomarkers are being investigated. Metabolomic studies have been attracting attention, and the aim of this study was to identify metabolomic biomarkers associated with AD and mild cognitive impairment (MCI). Of the 927 participants in the Nakayama Study conducted in Iyo City, Ehime Prefecture, 106 were selected for this study as Control (n = 40), MCI (n = 26), and AD (n = 40) groups, matched by age and sex. Metabolomic comparisons were made across the three groups. Then, correlations between metabolites and clinical symptoms were examined. The blood mRNA levels of the ornithine metabolic enzymes were also measured. Of the plasma metabolites, significant differences were found in ornithine, uracil, and lysine. Ornithine was significantly decreased in the AD group compared to the Control and MCI groups (Control vs. AD: 97.2 vs. 77.4; P = 0.01, MCI vs. AD: 92.5 vs. 77.4; P = 0.02). Uracil and lysine were also significantly decreased in the AD group compared to the Control group (uracil, Control vs. AD: 272 vs. 235; P = 0.04, lysine, Control vs. AD: 208 vs. 176; P = 0.03). In the total sample, the MMSE score was significantly correlated with lysine, ornithine, thymine, and uracil. The Barthel index score was significantly correlated with lysine. The instrumental activities of daily living (IADL) score were significantly correlated with lysine, betaine, creatine, and thymine. In the ornithine metabolism pathway, the spermine synthase mRNA level was significantly decreased in AD. Ornithine was decreased, and mRNA expressions related to its metabolism were changed in the AD group compared to the Control and MCI groups, suggesting an association between abnormal ornithine metabolism and AD. Increased betaine and decreased methionine may also have the potential to serve as markers of higher IADL in elderly persons. Plasma metabolites may be useful for predicting the progression of AD. (キーワード) Activities of Daily Living / Aged / Alzheimer Disease / Betaine / Biomarkers / Cognitive Dysfunction / Humans / Lysine / Ornithine / プラズマ (plasma) / RNA, Messenger / Thymine (徳島大学機関リポジトリ) ● Metadata: 2012846 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-022-19670-y (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36075959 ● Search Scopus @ Elsevier (PMID): 36075959 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-19670-y (徳島大学機関リポジトリ: 2012846, DOI: 10.1038/s41598-022-19670-y, PubMed: 36075959)
5.	Yukiko Tomioka, Makoto Kinoshita, Hidehiro Umehara, Tomohiko Nakayama, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Association between serum folate levels and schizophrenia based on sex., Psychiatry and Clinical Neurosciences, 74, 9, 466-471, 2020. (要約) Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels. (徳島大学機関リポジトリ) ● Metadata: 2008327 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/pcn.13074 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32445495 ● Search Scopus @ Elsevier (PMID): 32445495 ● Search Scopus @ Elsevier (DOI): 10.1111/pcn.13074 (徳島大学機関リポジトリ: 2008327, DOI: 10.1111/pcn.13074, PubMed: 32445495)

総説・解説:

1.	中山知彦, 富岡有紀子, 山田直輝, 梅原英裕, 木下誠, 中瀧理仁, 沼田周助 : 臨床現場におけるたとえ話, 精神科治療学, 37, 7, 745-749, 2022年7月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520856045142110592 (CiNii: 1520856045142110592)
2.	中山知彦, 沼田周助, 大森哲郎 : 精神病性うつ病, 精神科, 37, 3, 268-272, 2020年9月. (キーワード) psychotic depression / catatonic depression / involutional melancholia / DSM-5 / ICD-11 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520010381187289088 (CiNii: 1520010381187289088)

国際会議:

1.	Tomohiko Nakayama, Hiroaki Edo, Yoshida Tomohiro, Matsumoto Yui, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Nortriptyline Therapy of Treatment-Resistant Depression: two case reports, The CINP 2021 Virtual World Congress, Online, Feb. 2021.

国内講演発表:

1.	中山知彦, 松本唯, 富岡有紀子, 山田直輝, 中瀧理仁, 沼田周助 : 長期間維持電気けいれん療法を施行している遅発緊張病の一例, 第36回日本総合病院精神医学会総会, 2023年11月.
2.	塩田恭史, 中山知彦, 山田直輝, 中瀧理仁, 沼田周助 : 脳梗塞と転換症状の鑑別を要したうつ病の一例, 第63回中国・四国精神神経学会, 2023年11月.
3.	中山知彦, 梅原英裕, 富岡有紀子, 松本唯, 𠮷田朋広, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, 2023年11月.
4.	中山知彦, 梅原英裕, 富岡有紀子, 松本唯, 𠮷田朋広, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, 2023年9月.
5.	中山知彦, 六車隆太郎, 多田紗彩, 高原実香, 宮本亮介, 中瀧理仁, 和泉唯信, 沼田周助 : 難治性うつ病として治療中にレビー小体病が明らかとなった1症例, 第22回日本早期認知症学会学術大会, 2022年9月.
6.	富岡有紀子, 木下誠, 中山知彦, 梅原英裕, 中瀧理仁, 沼田周助 : 統合失調症患者におけるDNMT1と3aの遺伝子発現量の検討, 第16回日本統合失調症学会, 2022年3月.
7.	六車隆太郎, 多田紗彩, 中山知彦, 木下誠, 中瀧理仁, 沼田周助 : うつ病の治療経過中にパーキンソン病の併存が明らかになった1症例, 【第61回中国・四国精神神経学会, 2021年11月.
8.	青木真理子, 中山知彦, 富岡有紀子, 木下誠, 中瀧理仁, 沼田周助 : 診断に苦慮した遅発緊張病の一例, 第61回中国・四国精神神経学会, 2021年11月.

その他・研究会:

1.	中山知彦, 梅原英裕, 富岡有紀子, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 双極性障害における血中メタボローム解析, 第42回躁うつ病の薬理・生化学的研究懇話会, 2023年10月.
2.	中山知彦, 梅原英裕, 富岡有紀子, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 双極性障害における血中代謝物の変化, 第13回脳科学クラスターミニリトリート, 2022年2月.
3.	中山知彦, 梅原英裕, 富岡有紀子, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 沼田周助, 髙橋章, 岡本泰昌, 大森哲郎 : うつ病におけるキヌレニン経路の変化, 第40回躁うつ病の薬理・生化学的研究懇話会, 2021年10月.
4.	中山知彦, 梅原英裕, 富岡有紀子, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 沼田周助, 髙橋章, 岡本泰昌, 大森哲郎 : うつ病におけるキヌレニン経路の変化, 第12回脳科学クラスターミニリトリート, 2021年2月.
5.	中山知彦, 梅原英裕, 富岡有紀子, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 沼田周助, 髙橋章, 岡本泰昌, 大森哲郎 : うつ病におけるキヌレニン経路の変化, 第5回メタボロームシンポジウム, 2020年12月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

研究者番号（30872147）による検索